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a b s t r a c t 
Introduction: Familial hypercholesterolaemia (FH) is a common, heritable and preventable cause of premature 
coronary artery disease, with significant potential for positive impact on public health and healthcare savings. 
New clinical practice recommendations are presented in an abridged guidance to assist practitioners in enhancing 
the care of all patients with FH. 
Main recommendations: Core recommendations are made on the detection, diagnosis, assessment and manage- 
ment of adults, children and adolescents with FH. There is a key role for general practitioners (GPs) working in 
collaboration with specialists with expertise in lipidology. Advice is given on genetic and cholesterol testing and 
risk notification of biological relatives undergoing cascade testing for FH; all healthcare professionals should de- 
velop skills in genomic medicine. Management is under-pinned by the precepts of risk stratification, adherence to 
healthy lifestyles, treatment of non-cholesterol risk factors, and appropriate use of low-density lipoprotein (LDL)- 
cholesterol lowering therapies, including statins, ezetimibe and proprotein convertase subtilisin/kexin type 9 
(PCSK9) inhibitors. Recommendations on service design are provided in the full guidance. 
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Familial hypercholesterolaemia (FH) is a common and severe cause
f premature coronary atherosclerosis due to variants in genes affect-
ng the clearance of low-density lipoprotein (LDL)-cholesterol. FH is a
reventable cause of premature disease and death, with significant po-
ential for positive impact on public health and healthcare savings [ 1 ,
 ]. However, less than 10% of people with FH have been identified and,
f those treated, over 80% do not attain LDL-cholesterol targets [2] . 
The FH Australasia Network Consensus Group has developed a new
uidance to assist clinicians in the care of patients with FH, replacing
arlier recommendations [3] . This synopsis provides the key recom-
endations as actionable statements with their strength of evidence.
he full guidance, endorsed by several organisations (see appendix),
s available in Heart, Lung and Circulation at https://doi.org/10.1016/
.hlc.2020.09.943 [4] . 
. Method 
A steering committee, selected from board members of the FH Aus-
ralasia Registry Network [5] , appointed a writing group and invited
ontributions from diverse clinical specialties and health consumers [4] .
he protocols followed are detailed elsewhere [4] . Evaluation of the
ublished evidence on the care of FH was based on the GRADE sys-
em [ 4 , 6 ]. The totality of evidence, including expert opinion and patient
references, informed the recommendations. 
. Key evidenced-based recommendations 
Recommendations are presented with a class of recommendation
CoR) and level of evidence (LoE). Additional recommendations, includ-
ng lipoprotein apheresis and organisation of care, are given in the full
uidance [4] . 
Conversion factors in the recommendations are: for cholesterol, from
mol/L to mg/dL multiply mmol/L by 38.67; for triglycerides, from
mol/L to mg/dL multiply mmol/L by 88.57. 
.1. Phenotypic detection of index cases 
1. Several strategies should be considered for detecting index cases
of FH, including selective, opportunistic and universal screening
[ 1 , 2 , 7–10 ]. [CoR Moderate; LoE Moderate] 
2. Index cases should be sought by selective screening of adults with
premature atherosclerotic cardiovascular disease (ASCVD), primar-
ily coronary artery disease, and a family history of premature ASCVD
and/or hypercholesterolaemia [ 3 , 7 ]. [CoR Strong; LoE High] 
3. Opportunistic screening, based on a plasma LDL-cholesterol level
> 5.0 mmol/L, should be employed for detecting adults [8] . [CoR
Strong; LoE Moderate] 
4. Universal screening, based on an LDL-cholesterol level > 3.5 mmol/L,
should be considered before puberty (preferably between 1 and 2
years of age, coinciding with childhood immunisation) to initially
detect children with FH [ 1 , 9 ]. [CoR Moderate; LoE Moderate] 
5. Alerts on laboratory reports on lipid profiles should be employed to
enhance case detection [1] . [CoR Strong; LoE Moderate] 
6. Digital screening of electronic health records should be considered
to enable case detection [1] . [CoR Moderate; LoE Moderate] ese recommendations need to be utilised using judicious clinical judgement and
ents and families. Models of care need to be adapted to both local and regional
ew government funded schemes for genetic testing and use of PCSK9 inhibitors,
nomics Policy Framework, will enable adoption of these recommendations. A
ategy is, however, required to ensure that the guidance translates into benefit
7. The Dutch Lipid Clinic Network (DLCN) criteria ( Table 1 ) should
be used to make a phenotypic diagnosis of FH in adults but not in
children or adolescents [ 1 , 10 , 11 ]. [CoR Strong; LoE High] 
8. Patients with suspected FH should be referred to or discussed with a
specialist with expertise in lipidology for further assessment [ 3 , 7 , 8 ].
[CoR Strong; LoE Low] 
.2. Diagnosis and assessment of adults 
1. Secondary causes of hypercholesterolaemia should be excluded be-
fore making a diagnosis of FH (applies also to children and adoles-
cents) [ 3 , 7 , 10 , 11 ]. [CoR Strong; LoE High] 
2. The diagnosis of FH should be made using both phenotypic ( Table 1 )
and genetic criteria, but when genetic testing is not available the di-
agnosis should be made phenotypically [ 3 , 7 ]. [CoR Strong; LoE High]
3. Genetic testing (a Medicare rebatable item in Australia for index
cases with a high phenotypic probability of FH and for close rela-
tives of genetically confirmed index cases) should be used to confirm
the diagnosis of FH, especially if cascade testing is planned [ 3 , 7 , 12 ].
[CoR Strong; LoE High]; 
4. Patients should be risk assessed for the presence of other ma-
jor ASCVD risk factors, including elevated lipoprotein(a) [Lp(a)]
[ 3 , 13 , 14 ]. [CoR Strong; LoE Moderate] 
5. Cardiovascular risk prediction equations derived from the general
population should not be used in patients with FH [ 3 , 13 ]. [CoR
Strong; LoE Moderate] 
6. Coronary artery calcium score (CACS), computed tomography coro-
nary angiography (CTCA) and carotid ultrasonography may be con-
sidered for risk stratifying asymptomatic patients [ 3 , 10 , 11 , 15 , 16 ].
[CoR Weak; LoE Moderate] 
7. Adults with homozygous FH should be referred to a specialised cen-
tre for long-term care [ 7 , 17 ]. [CoR Strong; LoE High] 
.3. Diagnosis and assessment of children and adolescents 
1 Children suspected of having homozygous FH should be tested as
early as possible, at least by 2 years of age [ 7 , 10 , 17 ]. [CoR Strong;
LoE Moderate] 
2 Testing of children with suspected heterozygous FH using pheno-
typic and/or genotypic strategies should be considered between the
ages of 5 and 10 years [ 10 , 18 ]. [CoR Moderate; LoE Moderate] 
3 A probable phenotypic diagnosis of FH should be considered in those
with [ 10 , 18 , 19 ]: 
a LDL-cholesterol of > 5.0 mmol/L, with a parental history of hy-
percholesterolaemia or premature ASCVD; 
b LDL-cholesterol of 4.0 to 5.0 mmol/L, with a parental history of
hypercholesterolaemia or premature ASCVD; or 
c LDL-cholesterol of > 3.5 mmol/L, with a parent carrying a
pathogenic or likely pathogenic gene variant. [CoR Moderate; LoE
Moderate] 
4 Children and adolescents with heterozygous FH should be reviewed
by a paediatrician with expertise in lipidology [ 7 , 10 , 18 , 20 , 21 ]. [CoR
Strong; LoE Low] 
5 Genetic testing should be offered to diagnose children after a
pathogenic or likely pathogenic gene variant has been identified in
a parent or first-degree relative [ 1 , 3 , 19 ]. [CoR Strong; LoE Moderate]
6 Children should be risk stratified according to age, other ASCVD risk
factors, family history of premature ASCVD and the level of both
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Table 1 
The Dutch Lipid Clinic Network criteria for making the phenotypic diagnosis of familial hypercholesterolaemia in adult index cases [1–3] . For online use, 
please access the FH Australasia Network calculator at https://www.athero.org.au/fh/calculator/ . These criteria should not be used to diagnose FH in 
children or adolescents [10] . 
Criteria ∗ Score 
Section 1: Family history 
First degree relative with known premature coronary and/or vascular disease (men aged < 55 years, women aged < 60 years) 
OR First degree relative with known LDL-cholesterol above the 95th percentile for age and gender 
1 
First degree relative with tendinous xanthomata and/or arcus cornealis 
OR Children aged < 18 years with LDL-cholesterol above the 95th percentile for age and gender 
2 
Section 2: Personal history 
Patients with premature coronary artery disease (men aged < 55 years, women aged < 60 years) 2 
Patients with premature cerebral or peripheral vascular disease (men aged < 55 years, women aged < 60 years) 1 
Section 3: Physical examination 
Tendinous xanthomata 6 
Arcus cornealis before 45 years of age 4 
Section 3: Biochemical results: to convert cholesterol to mg/dL multiply mmol/L below by 38.67 
LDL-cholesterol (mmol/L) † 
LDL-cholesterol ≥ 8.5 8 
LDL-cholesterol 6.5–8.4 5 
LDL-cholesterol 5.0–6.4 3 
LDL-cholesterol 4.0–4.9 1 
Diagnosis Total Score 
Definite FH > 8 
Probable FH 6–8 
Possible FH 3–5 
Unlikely FH < 3 
∗ Note that only the highest score in each section is chosen to add up to the total score, to a maximum of 18. 
† If pre-treatment LDL-cholesterol is not available, use the FH Australasia Network’s online calculator ( https://www.athero.org.au/fh/calculator/ ) to 
















































LDL-cholesterol and Lp(a) at diagnosis [ 7 , 10 , 18 , 21 ]. [CoR Strong;
LoE Moderate] 
7 In children and adolescents with heterozygous FH, measurement of
carotid intima-medial thickness using carotid ultrasonography may
be considered to assess ASCVD risk [ 1 , 10 , 22 ]. [CoR Weak; LoE Mod-
erate] 
8 Children and adolescents with homozygous FH should be referred
on diagnosis to a specialist paediatric centre for planning of care
[ 7 , 10 , 17 , 21 , 23 ]. [CoR Strong; LoE High] 
.4. Genetic testing 
1. Diagnostic genetic testing and counselling should be offered to all
adult index cases with a probable/definite phenotypic diagnosis of
FH ( Table 1 ) [ 1 , 3 , 12 ]. [CoR Strong; LoE Moderate] 
2. Diagnostic genetic testing in an adult index case may be considered
when there is limited information to establish an accurate pheno-
typic diagnosis of FH [ 1 , 3 , 12 , 24 ]. [CoR Weak; LoE Moderate] 
3. Diagnostic genetic testing of children, as potential index cases,
should be considered when parents, or first-degree relatives, are un-
known or deceased, or as part of universal screening [ 1 , 3 , 9 ]. [CoR
Moderate; LoE Moderate] 
4. Genetic testing for FH should be carried out in an accredited labo-
ratory using standardised methods to detect pathogenic and likely
pathogenic gene variants causing FH [ 1 , 3 , 12 , 24 ]. [CoR Strong; LoE
High] 
5. Variants detected by genetic testing should be classified according
to the American College of Medical Genetic and Genomic standards
and guidelines, or a comparable classification [24–26] . [CoR Strong;
LoE High] 
6. If a pathogenic, or likely pathogenic, gene variant is not detected, FH
should not be excluded, particularly with a highly probable clinical
phenotype of FH [ 3 , 10 , 24 ]. [CoR Strong; LoE High] 
7. Diagnostic genetic testing of index cases with suspected FH should
be requested by a specialist (a requirement of the Medicare BenefitsSchedule in Australia) with appropriate skills in the care of patients
and families with FH [ 3 , 24 , 27 , 28 ]. [CoR Strong; LoE Low] 
8. All healthcare professionals involved in consenting families for ge-
netic testing should receive education in genomic medicine and have
basic skills in genetic counselling [ 1 , 3 , 24 , 28 , 29 ]. [CoR Strong; LoE
Low] 
.5. Cascade testing and risk notification of families 
1. Cascade testing (testing of consenting biological relatives of an in-
dividual with FH) should be carried out using both a phenotypic
and genotypic strategy ( Fig. 1 ), but if genetic testing is not available
a phenotypic strategy should be used [ 1–3 , 7 , 12 ]. [CoR Strong; LoE
High] 
2. Genetic testing is more cost-effective than phenotypic testing and
should be employed to screen family members after a pathogenic,
or likely pathogenic, gene variant has been identified in the family
[ 1 , 12 , 30 ]. [CoR Strong; LoE High] 
3. When genetic testing is not feasible, the diagnosis of FH in close
relatives should be made using age- and gender-specific plasma LDL-
cholesterol levels ( Table 2 ) [ 1–3 , 31 ]. [CoR Strong; LoE High] 
4. Risk notification of relatives should be consistent with local legis-
lation and institutional guidelines; risk notification may be indirect
(letter provided for notifier to give to relatives) or direct (letter sent
to relatives) [ 1–3 , 7 ]. [CoR Strong; LoE Low] 
5. Pre- and post-test genetic counselling should be offered to at risk
family members undergoing cascade testing [ 1–3 , 12 , 19 , 24 ]. [CoR
Strong; LoE High] 
6. Cascade testing and risk notification should be co-ordinated by a
well-resourced centre, particularly if employing genetic testing [ 1–
3 , 12 , 19 ]. [CoR Strong; LoE High] 
7. Genetic cascade testing may be undertaken by a GP (as specified by
the Medicare Benefits Schedule in Australia) with skills in the care of
FH, guided by an appropriate specialist [ 1–3 , 8 , 27 , 28 ]. [CoR Weak;
LoE Low] 
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Fig. 1. Scheme for cascade testing of biolog- 
ical relatives of an index case with confirmed 
familial hypercholesterolaemia. Adapted from 
Watts et al. 2011 [3] . 
ˆConsistent with relevant local legislation and 
institutional guidelines 
∗ According to age- and gender-specific plasma 
LDL-cholesterol concentrations published by 
Starr et al. [31] . 
Table 2 
Age-dependent LDL-cholesterol concentrations and thresholds (mmol/L; to convert to mg/dL multiply mmol/L by 38.67) to make a diagnosis of FH during 
cascade testing in (a) male and (b) female first-degree relatives of an index case. Adapted from Starr et al. [31] . 













































Fig. 2. Sequence of therapy for adults with familial hypercholesterolaemia 
(FH]. Most patients with heterozygous FH can be well controlled with a two- 
or three- drug combination; statin intolerant patients may be treated with eze- 
timibe and a PCSK9 inhibitor. Complex therapy regimens will usually apply to 
patients with homozygous FH [ 17 , 36 , 38 ], which may include children and ado- 
lescents. LDL-cholesterol targets are based on primary or secondary prevention 
settings [ 1 , 4 ]; patients should be on at least 3 months of therapy and above the 
targets before proceeding to next step. ∗ For targets, see Management of Adults 

















8. Genetic cascade testing should initially be prioritised for first-degree
relatives of a variant carrier and sequentially extended as additional
carriers are identified; if first-degree relatives decline testing, test-
ing should be extended to second-degree followed by third-degree
relatives (also applies to phenotypic testing alone) ( Fig. 1 ) [ 1–3 , 12 ].
[CoR Strong; LoE High] 
9. Universal screening of children should be coupled with child-parent
(reverse) cascade testing [ 1 , 9 , 20 ]. [CoR Strong; LoE Moderate] 
0. All healthcare professionals involved in cascade testing and risk no-
tification of families should receive education in genomic medicine
and have basic skills in genetic counselling [ 3 , 12 , 24 , 28 , 29 ]. [CoR
Strong; LoE Low] 
.6. Management of adults 
1. All adult patients with FH should be counselled on lifestyle modifica-
tions and non-cholesterol risk factors should be managed according
to expert recommendations [ 1 , 7 , 11 , 32 , 33 ]. [CoR Strong; LoE Moder-
ate] 
2. Care should employ shared decision making and address patients’
values and health literacy [ 1 , 7 , 34 ]. [CoR Strong; LoE Moderate] 
3. Therapy should initially aim for at least a 50% reduction in LDL-
cholesterol [ 1 , 11 , 13 , 35–37 ]. [CoR Strong; LoE Moderate] 
4. The following therapeutic targets should be considered [ 1 , 11 , 13 , 36–
38 ]: 
a LDL-cholesterol < 2.5 mmol/L (absence of ASCVD or other major
ASCVD risk factors); 
b LDL-cholesterol < 1.8 mmol/L (imaging evidence of ASCVD alone
or other major ASCVD risk factors); or 
c LDL-cholesterol < 1.4 mmol/L (presence of clinical ASCVD). [CoR
Moderate; LoE Moderate] 
5. Maximally tolerated high potency statins (eg. atorvastatin or ro-
suvastatin) with or without ezetimibe, and a heart-healthy diet,
should initially be employed to achieve the above targets ( Fig. 2 )
[ 1 , 2 , 36 , 39 ]. [CoR Strong; LoE High] 
6. A proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor
should be employed if the above LDL-cholesterol targets are not
achieved with maximally tolerated statins, ezetimibe and diet
( Fig. 2 ) [ 1 , 2 , 11 , 36 , 40 , 41 ]. [CoR Strong; LoE High] 
7. Patients with statin intolerance should be managed according to es-
tablished guidelines and treated with non-statins, including ezetim-
ibe and PCSK9 inhibitors [ 1 , 3 , 36 , 42 ]. [CoR Strong; LoE High] 
8. In FH patients with clinical ASCVD (or diabetes) on maximally tol-
erated statins and ezetimibe and elevated triglyceride levels (1.5–
5.6 mmol/L), use of high-dose omega-3 fatty acids (especially
4 g/day of pure eicosapentaenoic acid ethyl ester) should be con-
sidered to further reduce ASCVD risk [ 1 , 43 ]. [CoR Moderate; LoE
Moderate] 
9. Patients with FH should continue cholesterol-lowering drug thera-
pies during acute illness, such as respiratory infections, unless specif-
ically contra-indicated [ 4 , 44 , 45 ]. [CoR Strong; LoE Low] 
0. Plasma hepatic aminotransferases, creatine kinase, glucose and cre-
atinine should be measured before starting and dose titrating statin
therapy. Hepatic aminotransferases should be monitored regularly
and creatine kinase if musculoskeletal symptoms are reported; glu-
cose should be monitored if there is a risk of diabetes (these safety
checks also apply to children and adolescents) [ 1 , 3 , 4 , 7 ]. [CoR Strong;
LoE Moderate] 
1. All women of child-bearing age with FH should be offered pre-
pregnancy counselling, with individualised advice on contraception,
before starting a statin and this should be reinforced annually (ap-
plies also to adolescent girls) [ 1 , 3 , 7 ]. [CoR Strong; LoE Moderate] 
2. Statins and other systemically absorbed cholesterol lowering drugs
should be discontinued 3 months before conception, as well as dur-
ing pregnancy and breastfeeding [ 1 , 3 , 7 ]. [CoR Strong; LoE Moderate]3. In women with homozygous FH and clinical ASCVD, use of statins
and ezetimibe may be considered after the first trimester [ 1 , 5 , 36 ].
[CoR Weak; LoE Moderate] 
4. Although CACS may be useful for initial risk stratification of asymp-
tomatic patients prior to commencing a statin, it should not be used
to monitor the efficacy of therapy [ 1 , 15 , 16 , 46 ]. [CoR Strong; LoE
Moderate] 
5. In asymptomatic patients with heterozygous FH, carotid ultra-
sonography and CTCA may be used for monitoring the efficacy of
cholesterol-lowering therapy [ 1 , 15 , 22 ]. [CoR Weak; LoE Moderate] 
6. In adults with homozygous FH, carotid ultrasonography, CTCA,
echocardiography and exercise stress testing should be employed
(as clinically indicated) to assess progression of ASCVD and athero-
matous involvement of the aortic valve, with the aim of guiding
overall management (also applies to children with homozygous FH)
[ 7 , 15 , 38 ]. [CoR Strong; LoE Moderate] 
.7. Management of children and adolescents 
1. All patients and families with FH should be counselled on lifestyle
modifications, and advice to prevent or correct non-cholesterol risk
factors (especially smoking) [ 1 , 7 , 10 , 18 , 21 , 33 ]. [CoR Strong; LoE
Moderate] 







































































































2. Management should be based on shared decision making with par-
ents and offspring, with barriers to treatment adherence addressed
[ 1 , 7 , 10 , 34 ]. [CoR Strong; LoE Moderate] 
3. Initiation of statin treatment should be considered at age 8 to 10
years irrespective of gender; LDL-cholesterol targets in children and
adolescents need not be as intensive as in adults [ 1 , 7 , 10 , 18 , 22 ]. [CoR
Moderate; LoE Moderate] 
4. Earlier initiation of treatment with statins should be considered in
patients with a particularly adverse family history of ASCVD or other
major ASCVD risk factors [ 1 , 7 , 10 , 18 , 22 ]. [CoR Moderate; LoE Mod-
erate] 
5. In children with FH, aged 8 to 10 years on a suitable diet, an LDL-
cholesterol treatment target < 4.0 mmol/L or a 30–40% reduction
in LDL-cholesterol may be considered [ 1 , 10 , 18 , 21 ]. [CoR Weak; LoE
Low] 
6. In children with FH older than 10 years on a suitable diet, an LDL-
cholesterol treatment target < 3.5 mmol/L or a 50% reduction in
LDL-cholesterol may be considered [ 1 , 10 , 18 , 21 , 22 ]. [CoR Weak; LoE
Low] 
7. Statin therapy with or without ezetimibe, and a heart-healthy diet
with or without plant sterol (or stanol) supplementation, should be
employed to achieve the above targets [ 1 , 3 , 7 , 10 , 18 , 21 ]. [CoR Strong;
LoE High] 
8. Statins licenced for use in this age group (pravastatin, fluvastatin,
simvastatin In Australia) should be employed; ezetimibe is also li-
censed from the age of 10 years and should be used accordingly
[2–4] . [CoR Strong; LoE High] 
9. The use of atorvastatin and rosuvastatin should be considered in het-
erozygous FH according to clinical indications and shared decision
making [1–4] . [CoR Moderate, LoE High] 
0. The use of maximal doses of high potency statins and ezetimibe
should be considered in homozygous FH children as early as possi-
ble, preferably by the age of 2 years [ 1 , 4 , 10 , 21 , 47 ]. [CoR Moderate;
LoE Moderate] 
1. Although statins and ezetimibe can be safely used in children,
weight, growth, physical and sexual development, and well-being
should be monitored [ 1 , 3 , 4 , 10 , 18 , 21 , 48 ]. [CoR Strong; LoE High] 
2. Shared care between a paediatrician and a GP should be considered
for managing lower complexity patients [ 3 , 4 , 7 , 8 , 10 ]. [CoR Moder-
ate; LoE Low] 
3. Management should focus on the nuclear or the immediate family,
with at least an annual review of children; non-adherence should be
addressed [ 3 , 7 , 10 , 21 ]. [CoR Strong; LoE Low] 
4. Transition of adolescents to young adult services should be con-
sidered in advance, with support offered to enable ongoing self-
management and shared care into adulthood [ 3 , 4 , 18 , 48 ]. [CoR Mod-
erate; LoE Low] 
5. In children and adolescents with heterozygous FH, carotid ultra-
sonography may be employed to monitor therapy [ 1 , 10 , 22 , 49 ]. [CoR
Weak; LoE Moderate] 
6. In patients with homozygous FH, treatment should commence as
soon as possible after diagnosis: the LDL-cholesterol target should be
similar to adults, which may require addition of a PCSK9 inhibitor
to a statin and ezetimibe, as well as the use of lipoprotein apheresis
( Fig. 2 ) [ 1 , 7 , 10 , 17 , 18 , 23 , 38 ]. [CoR Strong; LoE Moderate] 
. Conclusion 
This guidance is aligned with a recent international call to action
n FH [50] . The recommendations need incorporation into healthcare
athways that meet the needs of the population [ 1 , 2 ]. In Australia,
overnment funded schemes that support appropriate genetic testing
nd use of PCSK9 monoclonal antibodies will contribute significantly
o enhancing the care of patients with FH [ 2 ]. The critical barrier that
eeds to be overcome is translating our guidance into health policy and
igh-quality care. Implementation research and practice [ 51 , 52 ] muste embraced as a national health priority to increase the impact of the
uidance on improving the care of all people with or at risk of FH. This
hallenge and recommendation applies globally to all countries aiming
o close major gaps in the care of FH [51] . 
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